Coverart for item
The Resource Handbook of Tuberculosis

Handbook of Tuberculosis

Label
Handbook of Tuberculosis
Title
Handbook of Tuberculosis
Creator
Contributor
Subject
Language
eng
Cataloging source
MiAaPQ
Literary form
non fiction
Nature of contents
dictionaries
Handbook of Tuberculosis
Label
Handbook of Tuberculosis
Link
http://libproxy.rpi.edu/login?url=https://ebookcentral.proquest.com/lib/rpi/detail.action?docID=4833911
Publication
Copyright
Related Contributor
Related Location
Related Agents
Related Authorities
Related Subjects
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • Abbreviations -- Contents -- Biography -- Chapter 1: Overview of Tuberculosis -- 1.1 History -- 1.2 Global Impact -- 1.3 Etiology -- 1.4 Epidemiology -- References -- Chapter 2: Clinical Features and Diagnosis of Tuberculosis: Primary Infection and Progressive Pulmonary Tuberculosis -- 2.1 Pathophysiology -- 2.2 Clinical Manifestations of Primary Pulmonary Tuberculosis -- 2.3 Progressive Primary Tuberculosis -- 2.4 Secondary/Reactivation Tuberculosis -- 2.4.1 Risk Factors -- 2.4.2 Clinical Signs and Symptoms of Patients with Postprimary Pulmonary Tuberculosis -- 2.5 Diagnosis of Pulmonary Tuberculosis -- 2.6 Diagnosis of Latent Tuberculosis Infection -- 2.7 Intrathoracic and Regional Spread of Tuberculosis -- 2.7.1 Miliary Pattern of Lung Involvement -- 2.7.2 Tuberculous Pleurisy -- 2.7.3 Regional Tuberculosis Lymphadenitis -- References -- Chapter 3: Treatment of Pulmonary Tuberculosis -- 3.1 Treatment of Active Tuberculosis Disease -- 3.1.1 Principles -- 3.1.2 Classes of Available Antituberculosis Drugs -- Isoniazid -- Rifamycins -- Pyrazinamide -- Ethambutol -- Fluoroquinolones -- Aminoglycosides -- Bedaquiline -- 3.1.3 Recommended Regimens -- 3.1.4 Duration of Treatment -- 3.1.5 Practical Aspects -- Directly Observed Therapy -- Case Management and Role of the Health Department -- Monitoring for Efficacy and Toxicity During Treatment -- Common Adverse Drug Reactions -- Drug-Drug Interactions -- Therapeutic Drug Monitoring -- Treatment Failure -- Recurrence -- Drug Resistance -- 3.2 Treatment of Latent Tuberculosis Infection -- 3.2.1 Principles -- Risk Groups -- Whom to Treat -- 3.2.2 Recommended Regimens -- Isoniazid -- Combination of Isoniazid plus Rifapentine -- Rifampin (Alone) -- Combination of Isoniazid plus Rifampin -- Treatment of Multidrug-Resistant LTBI -- 3.2.3 Practical Aspects -- Selecting a Regimen -- Special Populations
  • Adherence and Role of Directly Observed Therapy -- LTBI Patient Monitoring -- Interrupted LTBI Therapy -- Common Adverse Drug Reactions -- Drug-Drug Interactions -- References -- Chapter 4: Extrapulmonary Tuberculosis -- 4.1 Overview and Epidemiology -- 4.2 Overall Diagnosis and Treatment -- 4.3 Specific Considerations -- 4.3.1 Pleural Tuberculosis -- 4.3.2 Tuberculosis Lymphadenitis and Tuberculosis Abscess -- 4.3.3 Central Nervous System (CNS) Tuberculosis -- 4.3.4 Ocular Tuberculosis -- 4.3.5 Pericardial Tuberculosis -- 4.3.6 Skeletal Tuberculosis -- 4.3.7 Genitourinary Tuberculosis -- 4.3.8 Gastrointestinal Tuberculosis -- 4.3.9 Cutaneous Tuberculosis -- 4.3.10 Miliary Tuberculosis -- References -- Chapter 5: Public Health Issues -- 5.1 Introduction -- 5.2 Infection Control -- 5.3 Contact Tracing -- 5.4 Preventive Therapy -- 5.5 Conclusion -- References -- Chapter 6: Management of Tuberculosis in Special Populations -- 6.1 Tuberculosis in HIV-Infected Persons -- 6.1.1 Epidemiology -- 6.1.2 Prevention of Tuberculosis Disease -- 6.1.3 Clinical Presentation of Tuberculosis Disease -- 6.1.4 Diagnosis -- 6.1.5 Treatment Considerations -- 6.2 Pediatric Tuberculosis -- 6.2.1 Epidemiology of Pediatric Tuberculosis -- 6.2.2 Pathophysiology of Pediatric Tuberculosis -- 6.2.3 Presentations of Pediatric Tuberculosis -- 6.2.4 Diagnosis of Pediatric Tuberculosis -- 6.2.5 Treatment of Pediatric Tuberculosis -- 6.2.6 Prevention of Pediatric Tuberculosis -- 6.3 Drug-Resistant Tuberculosis -- 6.3.1 Definitions -- 6.3.2 Epidemiology of Drug-Resistant Tuberculosis -- 6.3.3 Primary and Acquired Resistance -- 6.3.4 Transmission Risk -- 6.3.5 Diagnostics for Drug Resistance -- 6.3.6 Treatment of DR-Tuberculosis -- 6.3.7 Preventive Chemotherapy -- References -- Chapter 7: Emerging Therapies -- 7.1 Introduction -- 7.2 The Drugs in Preclinical Development -- 7.2.1 Q203
  • 7.2.2 Benzothiazinones -- 7.3 The Newly Registered Anti-Tuberculosis Drugs and Related Molecules -- 7.3.1 The Diarylquinoline, Bedaquiline (TMC 207) -- 7.3.2 The Nitro-dihydro-imidazo-oxazoles -- 7.3.3 Delamanid (OPC-67683, Deltyba) -- 7.3.4 Pretomanid (PA-824) -- 7.3.5 TBA-354 -- 7.4 Drugs Repurposed for Their Anti-Tuberculosis Activity -- 7.4.1 The Oxazolidinones -- Linezolid -- Sutezolid -- Tedizolid -- 7.4.2 The Fluoroquinolones -- 7.4.3 The Ý-Lactams -- 7.5 Existing Tuberculosis Drugs on Reevaluation -- 7.5.1 Rifapentine -- 7.5.2 Clofazimine -- 7.6 Immunization and Vaccines -- 7.6.1 Vaccines -- 7.6.2 Host-Directed Therapies -- References -- Chapter 8: Conclusions and Future Directions -- References
http://library.link/vocab/cover_art
https://contentcafe2.btol.com/ContentCafe/Jacket.aspx?Return=1&Type=S&Value=9783319262734&userID=ebsco-test&password=ebsco-test
Dimensions
unknown
http://library.link/vocab/discovery_link
{'f': 'http://opac.lib.rpi.edu/record=b4387839'}
Extent
1 online resource (236 pages)
Form of item
online
Isbn
9783319262734
Media category
computer
Media MARC source
rdamedia
Media type code
c
Sound
unknown sound
Specific material designation
remote

Library Locations

    • Folsom LibraryBorrow it
      110 8th St, Troy, NY, 12180, US
      42.729766 -73.682577
Processing Feedback ...